HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • 'Keeping the Foot on the Gas' of HIV Research at CROI 2017

    When controversies arise, researchers return to the science. So at the Conference on Retroviruses and Opportunistic Infections (CROI) 2017, which will convene next week amid funding concerns and boycotts, researchers will be diving deep into the evidence.

    08 February 2017 | Medscape (requires free registration)
  • Worried About HIV and Aging? The First Thing to Do Is Stop Smoking

    There are people out there who are anxious about the impact HIV has on the aging process, but who continue to smoke. This is to be preoccupied by a threat that we don't quite understand and are not sure how to deal with, while neglecting a very real health threat that can be changed and brought under control.

    12 January 2017 | The Body
  • British team studies initiation of treatment shortly after HIV diagnosis

    A team of researchers in London, England, has reviewed the medical records of 113 men whose acute HIV infection was diagnosed at a sexual health clinic. The team found that most of the men (77%) initiated ART at their first clinic visit. Furthermore, they found that 99% of participants had an undetectable viral load within six months of initiating ART.

    21 December 2016 | CATIE
  • GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy

    GlaxoSmithKline PLC’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.

    20 December 2016 | Wall Street Journal
  • High rates of injury found among some HIV-positive people in B.C.

    Overall 14% of deaths among HIV-positive people were due to injury. In contrast, the figure among HIV-negative people was 6%. Furthermore, they stated that “the highest rates of injury among [HIV-positive] people were associated with falls and self-harm.” Among HIV-negative people, the top two causes of injury were “falls and motor vehicle accidents.”

    19 December 2016 | CATIE
  • Top 10 HIV Clinical Developments of 2016

    In typical years, a noteworthy development in the world of HIV would be the result of a landmark clinical trial or perhaps a gem of a lab study with a novel finding. But, 2016 was not typical. What made the most difference for people living with HIV and their health care providers this past year was less a paper published or presented than major shifts in our thinking about how best to prevent and manage HIV infection.

    02 December 2016 | The Body Pro
  • UNITAID and ANRS launch initiative in Cameroon to bring new HIV treatments to Africa

    A study launched in Yaoundé will test the latest generation of HIV treatment based on Dolutegravir under local conditions, with a view to establishing its viability in Africa. The results of the study are intended to inform the World Health Organization’s guidelines for the treatment of HIV patients in Africa. If successful, they will help to accelerate the opening of the market for these combinations to manufacturers of generic medicines and thereby reduce prices as well as improve access.

    17 November 2016 | UNITAID
  • Integrase inhibitors associated with improved viral suppression in HIV

    The integrase inhibitor Tivicay combined with low-dose Sustiva was associated with higher rates of long-term viral suppression than standard-dose Sustiva in patients with HIV, data from a network meta-analysis indicated.

    29 September 2016 | Healio
  • Four day a week ART: sub-optimal drug levels but few virological failures

    A poster at IAS 2016 reported on the effectiveness of a strategy in France to use reduced dose maintenance therapy. This involved only taking ART for four rather than seven days a week.

    20 September 2016 | HIV i-Base
  • Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

    I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

    20 September 2016 | BETA blog
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.